Nanobiotix SA

Voting Rights and Shares Capital of the Company

08 6 2023 16:15:00 提供 Nasdaq GlobeNewswire

NANOBIOTIX Provides First Quarter 2023 Operational and Financial Update

17 5 2023 16:15:00 提供 Nasdaq GlobeNewswire

NANOBIOTIX Entering Final Contract Negotiations Following Agreement to Non-Binding Term Sheet for Development and Commercialization of NBTXR3 With a Major Global Pharmaceutical Company

05 5 2023 01:30:00 提供 Nasdaq GlobeNewswire

NANOBIOTIX Provides Business Update and Reports Full Year 2022 Financial Results

24 4 2023 19:33:54 提供 Nasdaq GlobeNewswire

NANOBIOTIX to Provide Operational Update and Report Full Year 2022 Financial Results on April 24, 2023

17 4 2023 16:15:00 提供 Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

11 4 2023 16:15:00 提供 Nasdaq GlobeNewswire

Nanobiotix to Postpone Full Year 2022 Financial Results and Conference Call

27 3 2023 16:15:00 提供 Nasdaq GlobeNewswire

Nanobiotix to Provide Operational Update and Report Full Year 2022 Financial Results on March 28, 2023

14 3 2023 16:15:00 提供 Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

14 2 2023 16:15:00 提供 Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

11 1 2023 16:15:00 提供 Nasdaq GlobeNewswire

NANOBIOTIX Announces First Patient Randomized in the United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer

27 12 2022 01:45:00 提供 Nasdaq GlobeNewswire